The University of Michigan is offer a technology license for a nanotechnology involving cocrystallization. Cocrystallization is an essential processing step in the successful production of multi-component crystalline phases (cocrystals or crystalline molecular complexes of at least two components). The most generally applied techniques, crystallization by solvent evaporation, cooling solutions, and non-solvent methods, all suffer from the risk of crystallizing the single component phases thereby eliminating the possibility of accessing the multi-component crystalline phase. A cocrystalline product may contain pharmaceutical components or active pharmaceutical ingredients. There is a need for preparation of multi-component crystals that is both consistent and efficient.
University of Michigan researchers, led by Associate Professor of Pharmaceutical Sciences Nair Rodriguez-Hornedo with Yomaira J. Pagan, Christopher J. Falkiewicz, Kurt F. Seefeldt and Sarah Nehm, have created a novel and effective method for the synthesis of multi-component crystals by a reaction of the crystal components in solution, solid-liquid systems, or slurries.
University of Michigan researchers, led by Associate Professor of Pharmaceutical Sciences Nair Rodriguez-Hornedo with Yomaira J. Pagan, Christopher J. Falkiewicz, Kurt F. Seefeldt and Sarah Nehm, have created a novel and effective method for the synthesis of multi-component crystals by a reaction of the crystal components in solution, solid-liquid systems, or slurries.
This process does not involve grinding, co-grinding, solvent evaporation, or temperature variation. This invention also provides effective screening methods to rapidly prepare multi-component crystals in micro-phases and macro-phases under ambient conditions, in aqueous and organic solvents, and can be used in batch and continuous cocrystallization processes.
This method provides the ability to simultaneously synthesize cocrystals and control the particle size as well as the specific surface area of the cocrystalline product. It is applicable to the process of making pharmaceutical cocrystals where at least one of the cocrystal components is an active pharmaceutical ingredient.
Applications include isolation and large-scale synthesis of pharmaceutically active cocrystals. The advantages include: Ability to isolate multi-component crystalline phases; Isolation in shorter time periods and Production can be ramped up for large-scale manufacturing.
The process is applicable to chemical and biochemical process as well as chemical processing.
Persons or companies interested in the technology license should contact the University of Michigan Technology Transfer Office.
Applications include isolation and large-scale synthesis of pharmaceutically active cocrystals. The advantages include: Ability to isolate multi-component crystalline phases; Isolation in shorter time periods and Production can be ramped up for large-scale manufacturing.
The process is applicable to chemical and biochemical process as well as chemical processing.
Persons or companies interested in the technology license should contact the University of Michigan Technology Transfer Office.
Licensing Contact
Matthew Bell, 734-647-4738
msbell@umich.edu
Matthew Bell
Technology Licensing Specialist
1214 S. University Ave., 2nd Floor
Ann Arbor, MI 48104-2592
Tel: 734-647-4738
Fax: (734) 998-9630
Email: msbell@umich.edu
No comments:
Post a Comment